Improved Outcome of Enteric Peritonitis in Peritoneal Dialysis Patients Aged 50 Years and Older with Temporary Discontinuation of Peritoneal Dialysis and Intravenous Meropenem
Restricted accessResearch articleFirst published online May, 2017
Improved Outcome of Enteric Peritonitis in Peritoneal Dialysis Patients Aged 50 Years and Older with Temporary Discontinuation of Peritoneal Dialysis and Intravenous Meropenem
Peritonitis is a major cause of morbidity, mortality, and technique failure in peritoneal dialysis (PD) patients, especially when caused by enteric microorganisms (EM). We have implemented a treatment protocol specifically aimed at improving the outcome in EM peritonitis. The adapted protocol was applied in all PD patients 50 years and older presenting with peritonitis who were considered to be at risk of EM peritonitis and involves 3 interventions: 1) temporary discontinuation of PD without removing the catheter (peritoneal rest), 2) intravenous meropenem, and 3) meropenem intracatheter as lock (Mero-PerRest protocol).
Methods
In this observational study, we compared the outcome of 203 peritonitis episodes in 71 patients treated with the Mero-PerRest protocol, with 217 episodes in 104 patients treated with a more traditional intraperitoneal gentamicin-rifampicin-based regimen.
Results
In EM peritonitis episodes, the Mero-PerRest protocol resulted in a higher primary cure rate (90.0% vs 65.3%, adjusted odds ratio [OR] 4.54 [95% confidence interval (CI) 1.46 – 14.15]) and better technique survival (90.0% vs 69.4%, adjusted OR 3.41 [95% CI 1.07 – 10.87]). This effect was most distinct in patients with polymicrobial EM peritonitis (cure rate 87.5% vs 34.8%, p = 0.0003). Interestingly, primary cure rate (95.6% vs 84.7%, adjusted OR 3.92 [95% CI 1.37 – 11.19]) and technique survival (95.6% vs 85.6%, adjusted OR 3.60 [95% CI 1.25 – 10.32]) were also excellent in non-EM peritonitis episodes. Patient survival did not differ significantly.
Conclusion
The poor outcome of peritonitis caused by EM in PD patients aged 50 years and older could be improved by applying a treatment protocol involving temporary discontinuation of PD without catheter removal and intravenous and intracatheter meropenem.
JarvisE.M., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Predictors, treatment, and outcomes of non-Pseudomonas gram-negative peritonitis.Kidney Int2010; 78(4): 408–14.
2.
SzetoC., ChowV.C., ChowK., LaiR.W., ChungK., LeungC.Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases.Kidney Int2006; 69(7): 1245–52.
3.
EdeyM., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases.Nephrol Dial Transplant2010; 25(4): 1272–8.
4.
KernE.O., NewmanL.N., CachoC.P., SchulakJ.A., WeissM.F.Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination.Perit Dial Int2002; 22(3): 323–34.
5.
BunkeC.M., BrierM.E., GolferT.A.Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study.Kidney Int1997; 52(2): 524–9.
6.
HarwellC.M., NewmanL.N., CachoC.P., MulliganD.C., SchulakJ.A., FriedlanderM.A.Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis.Perit Dial Int1997; 17(6): 586–94.
SetyapranataS., HoltS.G.The gut in older patients on peritoneal dialysis.Perit Dial Int2015; 35(6): 650–4.
9.
WeizmanA.V., NguyenG.C.Diverticular disease: epidemiology and management.Can J Gastroenterol2011; 25(7): 385–9.
10.
ThalhammerF., HörlW.H.Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.Clin Pharmacokinet2000; 39(4): 271–9.
11.
BoerW.H., van AmptingJ.M.A., VosP.Successful treatment of eight episodes of Candida peritonitis without catheter removal using intracatheter administration of Amphotericin B.Perit Dial Int2007; 27(2): 208–10.
12.
De FijterC.W.H., ter WeeP.M., OeL.P., VerbrughH.A., FierenM.W.J.A., HuismanR.M.Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C)APD-related peritonitis: a prospective randomized multicenter comparison (CIPPER Trial).Perit Dial Int2001; 21(5): 480–6.
13.
BrulezH.F., MoncasiE.P., PosthumaN., ChoyK., ter WeeP.M.The efficacy of intraperitoneally administered gentamicin and rifampin as initial treatment of peritoneal dialysis-related peritonitis.Adv Perit Dial1995; 11: 182–6.
14.
RügerW., van IttersumF.J., ComazzettoL.F., HoeksS.E., ter WeeP.M.Similar peritonitis outcome in CAPD and APD patients with dialysis modality continuation during peritonitis.Perit Dial Int2011; 31(1): 39–47.
15.
HanleyJ.A., NegassaA., EdwardesM.D.D.B., ForresterJ.E.Statistical analysis of correlated data using generalized estimating equations: an orientation.Am J Epidemiol2003; 157(4): 364–75.
16.
BrownM.C., SimpsonK., KerssensJ.J., MactierR.A.Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007).Perit Dial Int2011; 31(6): 639–50.
17.
Del PesoG., BajoM.A., GadolaL., MillánI., CodoceoR., CeladillaO.Diverticular disease and treatment with gastric acid inhibitors do not predispose to peritonitis of enteric origin in peritoneal dialysis patients.Perit Dial Int2001; 21(4): 360–4.
18.
DavenportA.Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, peritonitis audit 2002–2003.Perit Dial Int2009; 29(3): 297–302.
BernardiniJ., BenderF., FlorioT., SloandJ., PalmMontalbanoL., FriedL.Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.J Am Soc Nephrol2005; 16(2): 539–45.
24.
CairnsH.S., BeckettJ., RudgeC.J., ThompsonF.D., MansellM.A.Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis.Clin Nephrol1989; 32(1): 27–30.
25.
UsbertiM., GazzottiR.M., MiletiM., BrazzoliA., ZuccaF., DepetriG.Treatment of acute peritonitis by temporary discontinuation of dialysis and low doses of oral ciprofloxacin in patients on CAPD.Perit Dial Int1994; 14(2): 185–6.
26.
WuG., KhannaR., VasS., OreopoulosD.G.Is extensive diverticulosis of the colon a contraindication to CAPD?Peritoneal Dial Bull1983; 3(4): 180–3.
27.
TranaeusA., HeimburgerO., GranqvistS.Diverticular disease of the colon: a risk factor for peritonitis in continuous peritoneal dialysis.Nephrol Dial Transplant1990; 5(2): 141–7.
28.
BustosE., RotellarC., MazzoniM.J., RakowskiT.A., ArgyW.P., WinchesterJ.F.Clinical aspects of bowel perforation in patients undergoing continuous ambulatory peritoneal dialysis.Seminars in Dialysis1994; 7(5): 355–9.
29.
SpitalA.Interruption of CAPD in the treatment of fecal peritonitis.Perit Dial Bull1984; 4: 55–6.
30.
NebelM.Peritonitisbehandlung bei Sigmadivertikulitis unter CAPD – konservativ oder operativ?Nieren – und Hochdruckkrankheiten1994; 23(Suppl 2): S134–6.
31.
LocatelliA., QuirogaM.A., De BenedettiL., GomezM., BaroneR., BarronM.C.Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter.Adv Perit Dial1995; 11: 176–8.
32.
GoupilR., Nadeau-FredetteA.C., TennankoreK.K., BargmanJ.M.Peritonitis caused by Veillonella species and Eggerthella lenta in peritoneal dialysis.Perit Dial Int2014; 34(2): 245–7.
33.
WesselingK.M., PierikR.G.J.M., OffermanJ.J.G.Laparoscopic therapy in a CAPD patient with perforated appendicitis without removal of the peritoneal catheter.Nephrol Dial Transplant2003; 18(9): 1929–30.
34.
MohrJ.F.IIIUpdate on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.Clin Infect Dis2008; 47(Suppl 1): S41–51.
35.
SolomkinJ.S.Evaluating evidence and grading recommendations: SIS/ IDSA guidelines for the treatment of complicated intra-abdominal infections.Surg Infect2010; 11(3): 269–74.
36.
LeeY.K., KimJ.K., OhS.E., LeeJ., NohJ.W.Successful antibiotic lock therapy in patients with refractory peritonitis.Clin Nephrol2009; 72(6): 488–91.
37.
van DuinD., DoiY.The global epidemiology of carbapenemase-producing Enterobacteriaceae.Virulence2016: 1–10.
